Pulmatrix (NASDAQ:PULM) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULMGet Rating) in a report released on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target (up from $5.00) on shares of Pulmatrix in a research report on Wednesday, March 30th.

Shares of Pulmatrix stock opened at $5.18 on Friday. The firm’s 50-day simple moving average is $5.77 and its 200-day simple moving average is $8.03. Pulmatrix has a twelve month low of $4.83 and a twelve month high of $23.40.

Pulmatrix (NASDAQ:PULMGet Rating) last released its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.83). Pulmatrix had a negative net margin of 426.00% and a negative return on equity of 37.38%. Research analysts forecast that Pulmatrix will post -6.04 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in PULM. Citadel Advisors LLC bought a new position in shares of Pulmatrix in the third quarter worth about $34,000. First Republic Investment Management Inc. raised its stake in shares of Pulmatrix by 400.0% in the third quarter. First Republic Investment Management Inc. now owns 50,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 40,000 shares during the last quarter. Parallax Volatility Advisers L.P. bought a new position in shares of Pulmatrix in the fourth quarter worth about $43,000. Murchinson Ltd. bought a new position in shares of Pulmatrix in the fourth quarter worth about $44,000. Finally, Virtu Financial LLC bought a new position in shares of Pulmatrix in the fourth quarter worth about $58,000.

Pulmatrix Company Profile (Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Read More

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.